Neteera
Last updated: Jul 31, 2026
Neteera develops contactless, radar-based patient monitoring that measures heart rate, respiratory rate, movement, sleep, and related activity without wearables, cameras, or direct skin contact. Its FDA-cleared platform is commercialized primarily for hospitals, post-acute care, skilled nursing, and senior living environments.
Visit WebsiteCompany Overview
Neteera Technologies develops an ambient patient-monitoring system built around high-frequency radar sensing and algorithms that interpret tiny skin and body movements. A sensor mounted near a bed measures cardio-respiratory micro-motion through clothing and bedding, then sends data to Neteera's HealthGate software for dashboards, trends, and alerts. The publicly documented FDA-cleared indication is narrower than the company's broader marketing: the 130H/131H Vital Sign Monitoring Sensor is cleared for adult heart-rate and respiratory-rate measurement in healthcare facilities and home monitoring, and is not intended to acutely treat potentially life-threatening situations. The product also exposes activity-oriented signals such as motion, position change, exit detection, and sleep-related metrics, with the exact clinical use and regulatory status varying by feature and market.
The commercial problem is persistent observation in settings where wired monitors and wearables are disruptive, labor-intensive, or poorly tolerated. Neteera targets hospitals, skilled nursing facilities, senior living, post-acute care, medical groups, payers, and home-care programs that want earlier visibility into deterioration and fewer unnecessary transfers. The company says its system is deployed in more than 36,000 devices globally and reports customer-statement-based outcome metrics, including an average five-day warning before hospitalization; those figures are useful traction signals but should be treated as vendor-reported rather than independently established clinical evidence. The product is delivered as a managed hardware, cloud, integration, and support workflow, including EHR connectivity and centralized monitoring.
Neteera has progressed beyond a prototype: FDA 510(k) clearance was granted in 2022, CE MDR certification is advertised by the company, and the company announced a $13 million Series B in 2023 followed by a $6.7 million extension led by Aescuvest with Foxconn participation. Its 2026 announcement of a GlobalMed and Smart Meter partnership gives it a route into the U.S. federal healthcare market, but this is a healthcare channel partnership rather than evidence of a defense contract. The business still faces the difficult execution layer common to clinical hardware: installation, workflow redesign, EHR integration, clinical validation by indication, reimbursement, procurement, and proving that alerts improve outcomes without creating new alarm burden.
The strategic and dual-use relevance is real but bounded. Radar-based, privacy-preserving measurement can be valuable for casualty monitoring in austere or contaminated environments, remote observation of patients who cannot wear sensors, and selected security or occupational-safety scenarios where physiological state is relevant. However, public materials reviewed for this record establish healthcare commercialization, not military deployment, border screening, or validated stress, deception, intoxication, or identity detection. Any defense thesis therefore depends on adaptation, additional testing, export and privacy review, and a separate procurement pathway. Neteera is strategically interesting as an allied contactless-sensing capability with an existing regulated product, while the primary diligence case remains healthcare execution rather than an assumed defense market.
Dual-Use Assessment
Neteera's radar sensing and signal-processing stack has credible non-healthcare adjacency because it can observe physiological motion without contact, cameras, or patient cooperation. Potential applications include remote monitoring of wounded personnel or patients in hazardous environments and carefully scoped security or occupational-safety screening. No public evidence reviewed here verifies defense deployment, military customers, or validated border-stress screening, so the dual-use case is technology-based optionality rather than demonstrated defense traction.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Neteera is a credible strategic-priority signal for a dual-use deep-tech database because it combines proprietary contactless radar sensing with a regulated medical product, disclosed deployments, and a Series B financing history. The strongest evidence supports a healthcare commercialization thesis: FDA clearance, CE MDR certification claims, a growing deployment footprint, and a 2026 federal-healthcare reseller route. The dual-use upside is plausible for remote casualty or hazardous-environment monitoring, but it is not yet supported by public defense contracts or military validation. Diligence should focus on recurring revenue, retention, alert sensitivity and specificity, clinical-economic outcomes, reimbursement, manufacturing quality, cybersecurity, and the cost and timeline of expanding indications. This flag is an internal strategic-priority assessment, not an investment recommendation.
Strategic Value to U.S.-Israel Alliance
Neteera offers allied access to a compact, privacy-preserving sensing capability that can collect cardio-respiratory and activity signals without attaching equipment to a person. That is relevant to healthcare resilience, aging-care staffing constraints, and remote or hazardous medical operations. Its strategic value is increased by FDA clearance, production activity, and a federal-healthcare channel, but should not be overstated as defense readiness: public evidence does not establish military procurement, classified use, or operational security-screening performance.
Key Technologies
- High-frequency radar micro-motion sensing
- Contactless ballistocardiographic measurement of heart and respiratory motion
- Signal processing and AI-derived physiological trends
- Through-clothing and through-bedding monitoring
- Bed-level activity, position-change, and exit detection
- Cloud dashboard, alerts, and EHR integration
Use Cases & Applications
- Continuous heart-rate and respiratory-rate monitoring in hospitals
- Skilled nursing and post-acute deterioration surveillance
- Senior living fall-risk, bed-exit, and repositioning workflows
- Home and remote patient monitoring without wearable compliance
- Sleep and recovery trend monitoring where cleared or permitted
- Casualty vital-sign observation in austere or contaminated medical settings
- Remote observation of patients who cannot reliably wear or manipulate sensors
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 8 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- neteera.com Public source used for profile verification.
- neteera.com Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- neteera.com Public source used for profile verification.
- neteera.com Public source used for profile verification.
- neteera.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Neteera may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Neteera's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.